|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2819-2827.
Prepublished online as a Blood First Edition Paper on June 25, 2007; DOI 10.1182/blood-2007-03-077792.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLE
Galectins in the tumor endothelium: opportunities for combined cancer therapy
Victor L. J. L. Thijssen1,
Françoise Poirier2,
Linda G. Baum3, and
Arjan W. Griffioen1
1 Angiogenesis Laboratory, Research Institute for Growth and Development (GROW), Department of Pathology, University Maastricht and Academic Hospital Maastricht, the Netherlands;
2 Institute Jacques Monod, Unité Mixte de Recherche, Centre National de la Recherche Scientifique (UMR CNRS) 7592, Paris, France;
3 Department of Pathology and Laboratory Medicine, University of California School of Medicine, Los Angeles, CA
Galectins are emerging as a family of proteins that play an important role in several steps of tumorigenesis. Evidence is accumulating that galectins are expressed by the tumor endothelium, where they contribute to different steps of tumor progression such as immune escape and metastasis. Recent studies have identified an important role for galectins in tumor angiogenesis. Moreover, it has been shown that galectins in the endothelium can be targeted for therapeutic applications. This opens a window of opportunity for the development of tumor-type independent treatment strategies. This review focuses on the expression of galectins in the tumor endothelium, their contribution to tumor progression, and their application in tumor-type independent cancer therapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. V Norling, M. Perretti, and D. Cooper
Endogenous galectins and the control of the host inflammatory response
J. Endocrinol.,
May 1, 2009;
201(2):
169 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Loser, A. Sturm, M. Voskort, V. Kupas, S. Balkow, M. Auriemma, C. Sternemann, A. U. Dignass, T. A. Luger, and S. Beissert
Galectin-2 Suppresses Contact Allergy by Inducing Apoptosis in Activated CD8+ T Cells
J. Immunol.,
May 1, 2009;
182(9):
5419 - 5429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. SAUSSEZ, C. DECAESTECKER, S. CLUDTS, P. ERNOUX, D. CHEVALIER, K. SMETANA Jr., S. ANDRE, X. LEROY, and H.-J. GABIUS
Adhesion/Growth-regulatory Tissue Lectin Galectin-1 in Relation to Angiogenesis/Lymphocyte Infiltration and Prognostic Relevance of Stromal Up-regulation in Laryngeal Carcinomas
Anticancer Res,
January 1, 2009;
29(1):
59 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gendronneau, S. S. Sidhu, D. Delacour, T. Dang, C. Calonne, D. Houzelstein, T. Magnaldo, and F. Poirier
Galectin-7 in the Control of Epidermal Homeostasis after Injury
Mol. Biol. Cell,
December 1, 2008;
19(12):
5541 - 5549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cederfur, E. Salomonsson, J. Nilsson, A. Halim, C. T Oberg, G. Larson, U. J Nilsson, and H. Leffler
Different affinity of galectins for human serum glycoproteins: Galectin-3 binds many protease inhibitors and acute phase proteins
Glycobiology,
May 1, 2008;
18(5):
384 - 394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Thijssen, S. Hulsmans, and A. W. Griffioen
The Galectin Profile of the Endothelium: Altered Expression and Localization in Activated and Tumor Endothelial Cells
Am. J. Pathol.,
February 1, 2008;
172(2):
545 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
